Rotella Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rotella Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-22,729	Closed	-$493K	–	311
2015 Q4	$493K	Buy	+22,729	New	+$442K	0.44%	23
2015 Q1	–	Sell	-12,729	Closed	-$164K	–	644
2014 Q4	$164K	Buy	+12,729	New	+$159K	0.14%	174

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Rotella Capital Management's HZNP Position: Q1 2016 in Review

Rotella Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2016, closing a stake of 22,729 shares — an estimated $493K sold.

Rotella Capital Management first reported a position in HZNP in Q4 2014 and held it in 2 quarters. The position peaked at $493K in Q4 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Rotella Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2016 after selling out during the quarter.
Rotella Capital Management sold 22,729 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $493K.
Rotella Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 2 quarters.
Rotella Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $493K in Q4 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.